Astaxanthin as a Possible Therapeutic Agent in Polyendocrine Metabolic Ovarian Syndrome (PMOS)

Polyendocrine metabolic ovarian syndrome (PMOS) — formerly known as polycystic ovary syndrome, or PCOS — is one of the most common hormone and metabolic disorders in women of reproductive age, affecting about 10% of women during their childbearing years.1 You might notice irregular menstrual cycles, acne, unwanted facial or body hair, weight gain, or difficulty…

Read Full News

Contributed: Reimagining therapeutic cornerstones for the immersive age

Clients have long used traditional tools such as journals, metaphor, movement and artwork to express what words alone could not capture. Today, immersive technologies offer new ways to explore and externalize the internal experience, building on those foundations while enabling more nuanced, embodied and precise forms of expression.  Individuals can construct symbolic environments that reflect emotional landscapes…

Read Full News

AION Labs launches CombinAble.AI to design antibodies for therapeutic development

Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of a new startup company CombineAble.AI, which will speed up the development of therapeutics by addressing challenges associated with antibody design.  CombinAble.AI was formed following an AION Labs startup challenge aimed at developing an AI-based solution for therapeutic…

Read Full News